| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2016: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we constructed a pluripotent-cell based system that simultaneously induces neuromuscular junctions (NMJs) which contain motor neurons, skeletal muscle, and Schwann cells (Lin CY, JCI insight 2019, patent pending). We also showed that spinal muscular atrophy can be used as a prototype for model construction and analysis of NMJ lesions in this system. In the future, we plan to use this unique system to analyze congenital myasthenic syndrome for which no specific treatment exists and spinal muscular atrophy for which the functional analysis of the disease-causing molecule has not been sufficiently advanced.
|
